Summit Therapeutics Set to Announce Q4 Earnings on February 23
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SMMT?
Source: seekingalpha
- Earnings Announcement: Summit Therapeutics (SMMT) is set to release its Q4 earnings on February 23 after market close, with a consensus EPS estimate of -$0.02, reflecting a 71.4% year-over-year improvement, indicating potential recovery in profitability.
- Revenue Expectations: The revenue estimate stands at $76.42 million, and despite SMMT beating EPS estimates only 38% of the time over the past two years and failing to exceed revenue estimates, this suggests limited market confidence in revenue growth.
- Estimate Revision Trends: Over the last three months, EPS estimates have seen four upward revisions and two downward adjustments, while revenue estimates experienced no upward revisions and one downward revision, highlighting analysts' mixed views on the company's future earnings potential.
- Market Reaction and Ratings: With its lead asset undergoing FDA review, Summit's stock has spiked, and recent rating upgrades suggest a cautiously optimistic outlook from the market regarding its future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SMMT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SMMT
Wall Street analysts forecast SMMT stock price to rise
12 Analyst Rating
8 Buy
3 Hold
1 Sell
Moderate Buy
Current: 15.870
Low
18.00
Averages
42.49
High
131.90
Current: 15.870
Low
18.00
Averages
42.49
High
131.90
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Summit Therapeutics Set to Announce Q4 Earnings on February 23
- Earnings Announcement: Summit Therapeutics (SMMT) is set to release its Q4 earnings on February 23 after market close, with a consensus EPS estimate of -$0.02, reflecting a 71.4% year-over-year improvement, indicating potential recovery in profitability.
- Revenue Expectations: The revenue estimate stands at $76.42 million, and despite SMMT beating EPS estimates only 38% of the time over the past two years and failing to exceed revenue estimates, this suggests limited market confidence in revenue growth.
- Estimate Revision Trends: Over the last three months, EPS estimates have seen four upward revisions and two downward adjustments, while revenue estimates experienced no upward revisions and one downward revision, highlighting analysts' mixed views on the company's future earnings potential.
- Market Reaction and Ratings: With its lead asset undergoing FDA review, Summit's stock has spiked, and recent rating upgrades suggest a cautiously optimistic outlook from the market regarding its future prospects.
See More
Summit Therapeutics to Host Q4 2025 Earnings Call
- Earnings Call Announcement: Summit Therapeutics will host its Q4 and full-year 2025 earnings call on February 23, 2026, after market close, expected to provide operational updates that highlight the company's latest advancements in the biopharmaceutical sector.
- Live Webcast Availability: The earnings call will take place at 4:30 PM ET and will be accessible via the company's website, allowing investors to receive real-time information, with an archived version also available for later reference, ensuring transparency and accessibility.
- Company Background: Founded in 2003, Summit Therapeutics focuses on developing patient-friendly medicinal therapies aimed at improving quality of life and addressing unmet medical needs, demonstrating its long-term commitment and growth potential in the biopharmaceutical industry.
- Forward-Looking Statement Caution: The company emphasizes that future expectations and plans may be influenced by various factors, including market conditions and clinical trial outcomes, advising investors to exercise caution regarding forward-looking statements.
See More
Growth Prospects for the EGFR-NSCLC Market Analyzed
- Market Size Forecast: The EGFR-NSCLC market is projected to reach $6 billion by 2024, with the U.S. accounting for approximately 56% of the total market, indicating strong demand for new therapies and significant economic potential in this region.
- Rising Patient Numbers: In 2024, nearly 117,000 new cases of EGFR-NSCLC are expected, and as testing rates increase, more patients with EGFR mutations are identified, driving the demand for targeted therapies and signaling ongoing market expansion.
- Active Drug Development: Several new drugs, including Zipalertinib and Firmonertinib, are in clinical trials and are anticipated to introduce new treatment options, which not only diversify the therapeutic landscape but also have the potential to redefine existing treatment standards and improve patient survival rates.
- Evolving Competitive Landscape: The convergence of TKIs, ADCs, and gene therapies is intensifying competition in the EGFR-NSCLC market, where future winners will depend on efficacy, resistance coverage, and combination therapy potential, driving innovation and growth in the industry.
See More
Exelixis and Summit Therapeutics: Promising Drug Candidates Ahead
- Exelixis Drug Progress: Exelixis is advancing its next-gen cancer drug zanzalintinib with an FDA application, expecting several phase 3 clinical trials in 2023; positive results could significantly boost stock prices and enhance its market position in oncology.
- Cabometyx Patent Cliff: With Cabometyx facing patent expiration by 2030, Exelixis is diversifying its product lineup through new drug development to ensure sustained growth and competitiveness in the market.
- Summit Drug Ivonescimab: Summit Therapeutics' ivonescimab has outperformed the best-selling drug Keytruda in trials and is undergoing 42 clinical studies; FDA approval could lead to a significant stock price increase by 2026.
- Massive Market Potential: Ivonescimab is projected to reach peak sales of $53 billion, and despite clinical and regulatory risks, its extensive range of indications showcases Summit's substantial potential in the biopharmaceutical sector.
See More
Exelixis and Summit Therapeutics: Future Prospects
- Exelixis Drug Progress: Exelixis is advancing its next-gen cancer drug zanzalintinib's FDA application, expected to replace Cabometyx by 2030, which would significantly enhance the company's market position in oncology.
- Clinical Trial Plans: Exelixis plans to initiate several phase 3 clinical trials this year and release two late-stage data sets, with positive results potentially driving stock price increases and ensuring continued growth before Cabometyx's patent expiration.
- Summit Drug Potential: Summit Therapeutics' ivonescimab has outperformed the best-selling drug Keytruda in comparative studies, and if it secures FDA approval in the U.S., it could significantly boost the company's stock price and market share.
- Extensive Clinical Research: Summit is conducting 42 clinical studies for ivonescimab, with analysts estimating peak sales could reach $53 billion, showcasing its vast potential across various indications despite clinical and regulatory risks.
See More
Summit Therapeutics Grants Stock Options to New Employees
- Stock Option Grants: Summit Therapeutics awarded a total of 257,368 stock options to 20 new employees, aimed at attracting and retaining talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Option Terms: The options have an exercise price of $16.56 per share and a ten-year term, reflecting the closing price on January 26, 2026, indicating the company's confidence in future stock performance.
- Vesting Schedule: The awarded options will vest in equal annual installments over four years, which not only incentivizes long-term employee retention but also enhances team stability and cohesion.
- Company Overview: Founded in 2003, Summit Therapeutics focuses on developing biopharmaceutical therapies that improve patient quality of life, listed on Nasdaq, showcasing its ongoing growth potential in the biopharmaceutical sector.
See More
Summit Therapeutics Set to Announce Q4 Earnings on February 23
- Earnings Announcement: Summit Therapeutics (SMMT) is set to release its Q4 earnings on February 23 after market close, with a consensus EPS estimate of -$0.02, reflecting a 71.4% year-over-year improvement, indicating potential recovery in profitability.
- Revenue Expectations: The revenue estimate stands at $76.42 million, and despite SMMT beating EPS estimates only 38% of the time over the past two years and failing to exceed revenue estimates, this suggests limited market confidence in revenue growth.
- Estimate Revision Trends: Over the last three months, EPS estimates have seen four upward revisions and two downward adjustments, while revenue estimates experienced no upward revisions and one downward revision, highlighting analysts' mixed views on the company's future earnings potential.
- Market Reaction and Ratings: With its lead asset undergoing FDA review, Summit's stock has spiked, and recent rating upgrades suggest a cautiously optimistic outlook from the market regarding its future prospects.
See More
Summit Therapeutics to Host Q4 2025 Earnings Call
- Earnings Call Announcement: Summit Therapeutics will host its Q4 and full-year 2025 earnings call on February 23, 2026, after market close, expected to provide operational updates that highlight the company's latest advancements in the biopharmaceutical sector.
- Live Webcast Availability: The earnings call will take place at 4:30 PM ET and will be accessible via the company's website, allowing investors to receive real-time information, with an archived version also available for later reference, ensuring transparency and accessibility.
- Company Background: Founded in 2003, Summit Therapeutics focuses on developing patient-friendly medicinal therapies aimed at improving quality of life and addressing unmet medical needs, demonstrating its long-term commitment and growth potential in the biopharmaceutical industry.
- Forward-Looking Statement Caution: The company emphasizes that future expectations and plans may be influenced by various factors, including market conditions and clinical trial outcomes, advising investors to exercise caution regarding forward-looking statements.
See More
Growth Prospects for the EGFR-NSCLC Market Analyzed
- Market Size Forecast: The EGFR-NSCLC market is projected to reach $6 billion by 2024, with the U.S. accounting for approximately 56% of the total market, indicating strong demand for new therapies and significant economic potential in this region.
- Rising Patient Numbers: In 2024, nearly 117,000 new cases of EGFR-NSCLC are expected, and as testing rates increase, more patients with EGFR mutations are identified, driving the demand for targeted therapies and signaling ongoing market expansion.
- Active Drug Development: Several new drugs, including Zipalertinib and Firmonertinib, are in clinical trials and are anticipated to introduce new treatment options, which not only diversify the therapeutic landscape but also have the potential to redefine existing treatment standards and improve patient survival rates.
- Evolving Competitive Landscape: The convergence of TKIs, ADCs, and gene therapies is intensifying competition in the EGFR-NSCLC market, where future winners will depend on efficacy, resistance coverage, and combination therapy potential, driving innovation and growth in the industry.
See More
Exelixis and Summit Therapeutics: Promising Drug Candidates Ahead
- Exelixis Drug Progress: Exelixis is advancing its next-gen cancer drug zanzalintinib with an FDA application, expecting several phase 3 clinical trials in 2023; positive results could significantly boost stock prices and enhance its market position in oncology.
- Cabometyx Patent Cliff: With Cabometyx facing patent expiration by 2030, Exelixis is diversifying its product lineup through new drug development to ensure sustained growth and competitiveness in the market.
- Summit Drug Ivonescimab: Summit Therapeutics' ivonescimab has outperformed the best-selling drug Keytruda in trials and is undergoing 42 clinical studies; FDA approval could lead to a significant stock price increase by 2026.
- Massive Market Potential: Ivonescimab is projected to reach peak sales of $53 billion, and despite clinical and regulatory risks, its extensive range of indications showcases Summit's substantial potential in the biopharmaceutical sector.
See More
Exelixis and Summit Therapeutics: Future Prospects
- Exelixis Drug Progress: Exelixis is advancing its next-gen cancer drug zanzalintinib's FDA application, expected to replace Cabometyx by 2030, which would significantly enhance the company's market position in oncology.
- Clinical Trial Plans: Exelixis plans to initiate several phase 3 clinical trials this year and release two late-stage data sets, with positive results potentially driving stock price increases and ensuring continued growth before Cabometyx's patent expiration.
- Summit Drug Potential: Summit Therapeutics' ivonescimab has outperformed the best-selling drug Keytruda in comparative studies, and if it secures FDA approval in the U.S., it could significantly boost the company's stock price and market share.
- Extensive Clinical Research: Summit is conducting 42 clinical studies for ivonescimab, with analysts estimating peak sales could reach $53 billion, showcasing its vast potential across various indications despite clinical and regulatory risks.
See More
Summit Therapeutics Grants Stock Options to New Employees
- Stock Option Grants: Summit Therapeutics awarded a total of 257,368 stock options to 20 new employees, aimed at attracting and retaining talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Option Terms: The options have an exercise price of $16.56 per share and a ten-year term, reflecting the closing price on January 26, 2026, indicating the company's confidence in future stock performance.
- Vesting Schedule: The awarded options will vest in equal annual installments over four years, which not only incentivizes long-term employee retention but also enhances team stability and cohesion.
- Company Overview: Founded in 2003, Summit Therapeutics focuses on developing biopharmaceutical therapies that improve patient quality of life, listed on Nasdaq, showcasing its ongoing growth potential in the biopharmaceutical sector.
See More
